H. LUNDBECK AS

Their core work

H. Lundbeck is a major Danish pharmaceutical company specialized in brain diseases, contributing industry expertise and clinical infrastructure to EU research consortia focused on neurodegenerative and neuropsychiatric disorders. They bring drug development capabilities, patient data access, and translational know-how to projects targeting Parkinson's disease, Alzheimer's disease, depression, and related conditions. Their role in H2020 is consistently that of a pharma industry partner providing real-world clinical context, compound libraries, and regulatory experience to academic-led consortia. They also invest in training the next generation of neuroscientists through multiple Marie Curie training networks.

What they specialise in

How they've shifted over time

In the early H2020 period (2015–2017), Lundbeck engaged broadly across regulatory science (ADAPT-SMART), digital health monitoring (RADAR-CNS with wearables for depression and epilepsy), and Alzheimer's real-world evidence (ROADMAP). From 2017 onward, their focus sharpened decisively toward molecular mechanisms of neurodegeneration — protein aggregation, mitochondrial dysfunction, alpha-synuclein imaging, and blood-brain barrier penetration. This shift reflects a company moving from exploratory health-system projects toward hard translational science aimed at specific druggable targets in Parkinson's and related diseases.

Lundbeck is doubling down on translational neuroscience — expect continued focus on Parkinson's drug targets, brain delivery methods, and iPSC-based disease models for CNS conditions.

How they like to work

Lundbeck exclusively joins consortia as a participant or third party — they have never coordinated an H2020 project, which is typical for large pharma companies that contribute industry resources rather than leading academic research programs. With 220 unique partners across 24 countries, they operate as a high-connectivity hub in European neuroscience networks, plugging into many different academic and clinical groups. Several projects are IMI (Innovative Medicines Initiative) public-private partnerships, where pharma companies co-invest alongside EU funding — indicating Lundbeck brings significant in-kind contributions beyond what EC funding figures show.

Lundbeck has collaborated with 220 distinct partners across 24 countries, making them one of the most broadly connected pharma industry partners in European neuroscience research. Their network spans major academic medical centers, neuroscience institutes, and other pharmaceutical companies across the EU.

What sets them apart

Lundbeck is one of few mid-size pharma companies entirely dedicated to brain diseases, which makes them a focused and committed industry partner — unlike diversified pharma giants that spread attention across many therapeutic areas. Their 18-project H2020 portfolio covers the full Parkinson's research pipeline from molecular targets (alpha-synuclein, TREM2) through delivery mechanisms (BBB, intracerebral) to patient monitoring (digital biomarkers), giving them unusually integrated knowledge. For consortium builders, Lundbeck offers a rare combination: genuine pharma industry infrastructure with deep neuroscience specialization and no competing therapeutic distractions.

Highlights from their portfolio

• TreatER
  A clinical proof-of-concept study for CDNF protein delivered directly into the brain for Parkinson's disease — one of Lundbeck's most translational and disease-specific H2020 commitments.
• EHDEN
  A large-scale European health data harmonization initiative (OMOP CDM/OHDSI) running until 2024, positioning Lundbeck at the intersection of real-world evidence and federated data infrastructure.
• IM2PACT
  Addresses the blood-brain barrier challenge using iPSC models — a critical bottleneck for all CNS drug development, with direct implications for Lundbeck's entire pipeline.